Investor Presentaiton

Immunology LPA₁ Sotyktu CD19 NEX T SLE Phase 3 registrational program (POETYK-SLE-11 and POETYK-SLE-2² parallel studies) Inclusion Criteria: • SLEDAI-2K > 6 with skin and/or joint involvement BILAG: 1A or 2Bs . Seropositivity R • Stable background therapy 1:1 • No severe organ- threatening disease Primary Endpoint: SRI(4) at Week 52 1. NCT05617677; 2. NCT05620407 Ill Bristol Myers Squibb™ Primary Endpoint Week 52 deucravacitinib 3 mg BID + SoC Placebo + SoC Optional long-term extension and follow-up Data anticipated in 2026 Not for Product Promotional Use 64

View entire presentation